NSCIF and 1N1 Related Headlines
Go Back- Nanalysis Announces First Quarter 2026 Results
- Nanalysis Announces First Quarter 2026 Conference Call
- Nanalysis Announces Board Transition and Appointment of Three New Directors
- Nanalysis Announces Fourth Quarter and Full Year 2025 Results
- Nanalysis Announces Fourth Quarter and Full Year 2025 Conference Call
- Nanalysis Announces Grant of Options and Restricted Share Units
- Nanalysis Announces Closing of Second Tranche to Complete its $3.4 Million Offering
- Nanalysis closes $2.5 million first tranche, upsizes private placement
- Nanalysis Announces Upsize to Private Placement and Closing of the First Tranche
- Nanalysis Scientific announces $2.5 million private placement
- Nanalysis Announces $2.5 Million Private Placement
- Nanalysis Announces Third Quarter 2025 Results
- Nanalysis Announces Third Quarter 2025 Conference Call
- Nanalysis Announces Change of Management
- Nanalysis announces support from Wiley for NMR Instruments in KnowItAll 2026
- Nanalysis Chosen by IMRIS as Critical Component MRI Supplier
- Nanalysis Announces Second Quarter 2025 Results
- Nanalysis Announces Second Quarter 2025 Conference Call
- Nanalysis Announces First Regulated Assay for Pharmaceutical Quality Control via Benchtop NMR Accepted by the United States Pharmacopeia (USP) and European Pharmacopeia (Ph. Euro)
NSCIF and 1N1 Related Press Releases
Go Back- Nanalysis Announces First Quarter 2026 Results
- Nanalysis Announces First Quarter 2026 Conference Call
- Nanalysis Announces Board Transition and Appointment of Three New Directors
- Nanalysis Announces Fourth Quarter and Full Year 2025 Results
- Nanalysis Announces Fourth Quarter and Full Year 2025 Conference Call
- Nanalysis Announces Grant of Options and Restricted Share Units
- Nanalysis Announces Closing of Second Tranche to Complete its $3.4 Million Offering
- Nanalysis Announces Upsize to Private Placement and Closing of the First Tranche
- Nanalysis Announces $2.5 Million Private Placement
- Nanalysis Announces Third Quarter 2025 Results
- Nanalysis Announces Third Quarter 2025 Conference Call
- Nanalysis Announces Change of Management
- Nanalysis announces support from Wiley for NMR Instruments in KnowItAll 2026
- Nanalysis Chosen by IMRIS as Critical Component MRI Supplier
- Nanalysis Announces Second Quarter 2025 Results
- Nanalysis Announces Second Quarter 2025 Conference Call
- Nanalysis Announces First Regulated Assay for Pharmaceutical Quality Control via Benchtop NMR Accepted by the United States Pharmacopeia (USP) and European Pharmacopeia (Ph. Euro)
